罗娜治疗师的新SiRNA疗法取得了有希望的成果,大大降低了胆固醇和PCSK9水平。 Rona Therapeutics' new siRNA therapy shows promising results, reducing cholesterol and PCSK9 levels significantly.
罗娜治疗学在2024年美国心脏协会科学会议上介绍了RN0191的第一阶段试验结果,这是针对PCSK9的SiRNA疗法,取得了积极的结果。 Rona Therapeutics presented positive Phase 1 trial results for RN0191, an siRNA therapy targeting PCSK9, at the 2024 American Heart Association Scientific Sessions. 治疗结果显示,PCSK9减少95%,LDL胆固醇减少74%,效果长达6个月。 The treatment showed up to a 95% reduction in PCSK9 and up to 74% reduction in LDL cholesterol, with effects lasting up to 6 months. 该疗法修补得很好,支持其作为高胆固醇双年度治疗的潜力,高胆固醇是心脏病的一个风险因素。 The therapy was well-tolerated, supporting its potential as a bi-annual treatment for high cholesterol, a risk factor for heart disease.